Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -755.79% is 23% above its 5-year average of -977.90%, near the high end of its 5-year range (-3786.68%–-250.03%).
47.32% above its 12-month average of -1434.61%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1522.83%.
EBITDA MARGIN
-755.79%
EBITDA MARGIN AVG TTM
-1434.61%
EBITDA MARGIN AVG 3Y
-865.96%
EBITDA MARGIN AVG 5Y
-977.90%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+47.32%
CURRENT VS 3Y AVG
+12.72%
CURRENT VS 5Y AVG
+22.71%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Recursion Pharmaceuticals, Inc.
Market Cap
$2.13B
EBITDA Margin
-755.79%
TTM Avg
-1434.61%
3Y Avg
-865.96%
5Y Avg
-977.90%
Market Cap
$2.49B
EBITDA Margin
-270.04%
TTM Avg
-444.88%
3Y Avg
-365.27%
5Y Avg
-89273.54%
Market Cap
$1.74B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$1.71B
EBITDA Margin
-628.14%
TTM Avg
-766.74%
3Y Avg
-948.44%
5Y Avg
-801.32%
Market Cap
$2.72B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$1.01B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$470.35M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
Market Cap
$389.98M
EBITDA Margin
-48.80%
TTM Avg
-44.09%
3Y Avg
-45.35%
5Y Avg
-45.35%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | $2.13B | -755.79% | -1434.61% | -865.96% | -977.90% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.49B | -270.04% | -444.88% | -365.27% | -89273.54% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 16.41% | 1.22% | -1.65% | 4.31% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | -628.14% | -766.74% | -948.44% | -801.32% |
| TransMedics Group, Inc. (TMDX)vs › | $2.72B | 22.42% | 17.70% | -0.76% | -37.34% |
| Teladoc Health, Inc. (TDOC)vs › | $1.01B | 3.96% | -13.21% | -146.19% | -104.68% |
| NeoGenomics, Inc. (NEO)vs › | $470.35M | 0.24% | -1.36% | -6.49% | -5.53% |
| NRC Health (NRC)vs › | $459.30M | 21.99% | 25.40% | 28.98% | 31.97% |
| Shoulder Innovations, Inc. (SI)vs › | $389.98M | -48.80% | -44.09% | -45.35% | -45.35% |
| PDS Biotechnology Corporation (PDSB)vs › | $41.24M | N/A | N/A | N/A | N/A |
Gross Margin
-62.0%
EBITDA Margin
-755.8%
Operating Margin
-867.9%
Net Margin
-945.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1522.83% |
| 2026-03-31 | -1681.58% |
| 2025-12-31 | -250.03% |
| 2025-09-30 | -2920.95% |
| 2025-06-30 | -797.67% |
| 2025-03-31 | -1166.75% |
| 2024-12-31 | -3786.68% |
| 2024-09-30 | -349.50% |
| 2024-06-30 | -635.76% |
| 2024-03-31 | -659.42% |
| 2023-12-31 | -860.10% |
| 2023-09-30 | -910.43% |
| 2023-06-30 | -691.47% |
| 2023-03-31 | -545.06% |
| 2022-12-31 | -422.40% |
| 2022-09-30 | -456.48% |
| 2022-06-30 | -828.50% |
| 2022-03-31 | -1004.23% |
| 2021-12-31 | -2495.36% |
| 2021-09-30 | -1758.64% |
| 2021-06-30 | -1543.92% |
| 2021-03-31 | -1163.28% |
| 2020-12-31 | -939.12% |
| 2020-09-30 | -2507.77% |
